Day One Biopharmaceuticals
Paediatric-first oncology company whose tovorafenib became the first targeted therapy for childhood low-grade glioma.
Ojemda (tovorafenib) US approval 2024; Ipsen holds ex-US rights; LOGGIPY-2 first-line phase 3; pimasertib (MEK) combinations.
Pages like this
not linked directly; found by shared links- CompanyIpsen
Shares Tovorafenib, Glioma & glioblastoma.
- IdeaDevelop drugs in children first when the target is a children's target
Shares Tovorafenib, Rare and paediatric cancers without markets, Glioma & glioblastoma.
- InstitutionGreat Ormond Street Hospital for Children
Shares Rare and paediatric cancers without markets, Glioma & glioblastoma.
- IdeaAdvance market commitments for paediatric and rare cancer drugs
Shares Rare and paediatric cancers without markets, Glioma & glioblastoma.
- InstitutionThe Hospital for Sick Children (SickKids)
Shares Rare and paediatric cancers without markets, Glioma & glioblastoma.
- InstitutionPrincess Máxima Center for Pediatric Oncology
Shares Rare and paediatric cancers without markets, Glioma & glioblastoma.
- InstitutionSIOP Europe – European Society for Paediatric Oncology
Shares Rare and paediatric cancers without markets, Glioma & glioblastoma.
- TargetGD2 (disialoganglioside)
Shares Rare and paediatric cancers without markets, Glioma & glioblastoma.